Cargando…

Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine

The toxicity of mRNA-lipid nanoparticle (LNP) vaccines depends on the total mRNA-LNP dose. We established that the maximum tolerated dose of our trivalent mRNA-LNP genital herpes vaccine was 10 μg/immunization in mice. We then evaluated one of the mRNAs, gD2 mRNA-LNP, to determine how much of the 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Hook, Lauren M., Awasthi, Sita, Cairns, Tina M., Alameh, Mohamad-Gabriel, Fowler, Bernard T., Egan, Kevin P., Sung, Molly M. H., Weissman, Drew, Cohen, Gary H., Friedman, Harvey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953786/
https://www.ncbi.nlm.nih.gov/pubmed/35336946
http://dx.doi.org/10.3390/v14030540
_version_ 1784675935664996352
author Hook, Lauren M.
Awasthi, Sita
Cairns, Tina M.
Alameh, Mohamad-Gabriel
Fowler, Bernard T.
Egan, Kevin P.
Sung, Molly M. H.
Weissman, Drew
Cohen, Gary H.
Friedman, Harvey M.
author_facet Hook, Lauren M.
Awasthi, Sita
Cairns, Tina M.
Alameh, Mohamad-Gabriel
Fowler, Bernard T.
Egan, Kevin P.
Sung, Molly M. H.
Weissman, Drew
Cohen, Gary H.
Friedman, Harvey M.
author_sort Hook, Lauren M.
collection PubMed
description The toxicity of mRNA-lipid nanoparticle (LNP) vaccines depends on the total mRNA-LNP dose. We established that the maximum tolerated dose of our trivalent mRNA-LNP genital herpes vaccine was 10 μg/immunization in mice. We then evaluated one of the mRNAs, gD2 mRNA-LNP, to determine how much of the 10 μg total dose to assign to this immunogen. We immunized mice with 0.3, 1.0, 3.0, or 10 μg of gD2 mRNA-LNP and measured serum IgG ELISA, neutralizing antibodies, and antibodies to six crucial gD2 epitopes involved in virus entry and spread. Antibodies to crucial gD2 epitopes peaked at 1 μg, while ELISA and neutralizing titers continued to increase at higher doses. The epitope results suggested no immunologic benefit above 1 μg of gD2 mRNA-LNP, while ELISA and neutralizing titers indicated higher doses may be useful. We challenged the gD2 mRNA-immunized mice intravaginally with HSV-2. The 1-μg dose provided total protection, confirming the epitope studies, and supported assigning less than one-third of the trivalent vaccine maximum dose of 10 μg to gD2 mRNA-LNP. Epitope mapping as performed in mice can also be accomplished in phase 1 human trials to help select the optimum dose of each immunogen in a multivalent vaccine.
format Online
Article
Text
id pubmed-8953786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89537862022-03-26 Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine Hook, Lauren M. Awasthi, Sita Cairns, Tina M. Alameh, Mohamad-Gabriel Fowler, Bernard T. Egan, Kevin P. Sung, Molly M. H. Weissman, Drew Cohen, Gary H. Friedman, Harvey M. Viruses Article The toxicity of mRNA-lipid nanoparticle (LNP) vaccines depends on the total mRNA-LNP dose. We established that the maximum tolerated dose of our trivalent mRNA-LNP genital herpes vaccine was 10 μg/immunization in mice. We then evaluated one of the mRNAs, gD2 mRNA-LNP, to determine how much of the 10 μg total dose to assign to this immunogen. We immunized mice with 0.3, 1.0, 3.0, or 10 μg of gD2 mRNA-LNP and measured serum IgG ELISA, neutralizing antibodies, and antibodies to six crucial gD2 epitopes involved in virus entry and spread. Antibodies to crucial gD2 epitopes peaked at 1 μg, while ELISA and neutralizing titers continued to increase at higher doses. The epitope results suggested no immunologic benefit above 1 μg of gD2 mRNA-LNP, while ELISA and neutralizing titers indicated higher doses may be useful. We challenged the gD2 mRNA-immunized mice intravaginally with HSV-2. The 1-μg dose provided total protection, confirming the epitope studies, and supported assigning less than one-third of the trivalent vaccine maximum dose of 10 μg to gD2 mRNA-LNP. Epitope mapping as performed in mice can also be accomplished in phase 1 human trials to help select the optimum dose of each immunogen in a multivalent vaccine. MDPI 2022-03-05 /pmc/articles/PMC8953786/ /pubmed/35336946 http://dx.doi.org/10.3390/v14030540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hook, Lauren M.
Awasthi, Sita
Cairns, Tina M.
Alameh, Mohamad-Gabriel
Fowler, Bernard T.
Egan, Kevin P.
Sung, Molly M. H.
Weissman, Drew
Cohen, Gary H.
Friedman, Harvey M.
Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title_full Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title_fullStr Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title_full_unstemmed Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title_short Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine
title_sort antibodies to crucial epitopes on hsv-2 glycoprotein d as a guide to dosing an mrna genital herpes vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953786/
https://www.ncbi.nlm.nih.gov/pubmed/35336946
http://dx.doi.org/10.3390/v14030540
work_keys_str_mv AT hooklaurenm antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT awasthisita antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT cairnstinam antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT alamehmohamadgabriel antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT fowlerbernardt antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT egankevinp antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT sungmollymh antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT weissmandrew antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT cohengaryh antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine
AT friedmanharveym antibodiestocrucialepitopesonhsv2glycoproteindasaguidetodosinganmrnagenitalherpesvaccine